Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adynxx, Inc.ALQA · Entity 155807 | Director | June 30, 2017 | July 03, 2017 |
| Beyond Air, Inc.AITB · Entity 8379 | Director | March 14, 2017 | April 19, 2017 |
| MetaStat, Inc.MTST · Entity 170270 | Director | October 11, 2017 | November 21, 2017 |
| NEXGEL, INC.NXGL · Entity 8400 | Director | June 25, 2025 | June 28, 2025 |
| NexImmune, Inc.NEXI · Entity 89921 | Executive VP of Research & Dev | April 05, 2022 | April 07, 2022 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
| SOLIGENIX, INC.SNGX · Entity 8067 | Director | October 12, 2026 | October 13, 2026 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | See Remarks | November 26, 2018 | November 27, 2018 |
| Streamex Corp.BSGM · Entity 1816 | Director | July 14, 2020 | July 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adynxx, Inc.
Report date June 30, 2017 · Filed July 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2027-06-30 | Direct | 90,000 |
Reported balance
After 2017-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-30 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests in eleven equal monthly installments with one-eleventh (1/11) vesting on the thirtieth (30th) day of each of the next eleven (11) months (or, if there is no 30th day in a month, on the last day of that month), with the first such vesting date occurring on July 30, 2017, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in eleven equal monthly installments with one-eleventh (1/11) vesting on the thirtieth (30th) day of each of the next eleven (11) months (or, if there is no 30th day in a month, on the last day of that month), with the first such vesting date occurring on July 30, 2017, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan.
Beyond Air, Inc.
Report date March 14, 2017 · Filed April 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,927 |
Reported balance
Holding disclosure · report date 2017-03-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,927 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2024-07-24 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The options vest in 3 equal annual installments beginning on July 11, 2014. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2025-09-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: The options vest in 3 equal annual installments beginning on September 3, 2015. |
| RSUSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2025-09-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The restricted shares will become exercisable in 3 equal annual installments beginning on September 3, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in 3 equal annual installments beginning on July 11, 2014.
F2: The restricted shares will become exercisable in 3 equal annual installments beginning on September 3, 2015.
F3: The options vest in 3 equal annual installments beginning on September 3, 2015.
MetaStat, Inc.
Report date October 11, 2017 · Filed November 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2017-10-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-11 · Exercise / conversion · Acquired 50,000 · Balance 50,000 F1: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock. F2: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock.
F2: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control.
NEXGEL, INC.
Report date June 25, 2025 · Filed June 28, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2035-06-25 | Direct | 30,000 |
Reported balance
After 2025-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-25 · Grant · Acquired 30,000 · Balance 30,000 F1: Represents a stock option granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended (the "Plan"), for services as a member of the Issuer's Board of Directors until; the Issuer's 2026 Annual Meeting of Stockholder. The number of shares underlying the stock option shall vest as follows: in equal 2,500 share amounts over the continuous twelve months (on the last calendar day of each month) beginning on July 31, 2025, subject to the Reporting Person's continuous service through each vesting date. In the event of a Change in Control (as defined in the Plan), any unvested shares underlying the stock option shall accelerate in accordance with the terms of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended (the "Plan"), for services as a member of the Issuer's Board of Directors until; the Issuer's 2026 Annual Meeting of Stockholder. The number of shares underlying the stock option shall vest as follows: in equal 2,500 share amounts over the continuous twelve months (on the last calendar day of each month) beginning on July 31, 2025, subject to the Reporting Person's continuous service through each vesting date. In the event of a Change in Control (as defined in the Plan), any unvested shares underlying the stock option shall accelerate in accordance with the terms of the Plan.
NexImmune, Inc.
Report date April 05, 2022 · Filed April 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2032-04-04 | Direct | 80,100 |
Reported balance
After 2022-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-05 · Grant · Acquired 80,100 · Balance 80,100 F1: 25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Zeldis's continued service to the corporation on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Zeldis's continued service to the corporation on each vesting date.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,500 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 22,500 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death.
F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
SOLIGENIX, INC.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $549.60 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-12 · Disposition to issuer · Disposed 54 · Balance 0 F1: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $400.80 · Expires 2028-09-26 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-12 · Disposition to issuer · Disposed 74 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $232.80 · Expires 2029-09-05 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-12 · Disposition to issuer · Disposed 128 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $472.80 · Expires 2030-09-15 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-12 · Disposition to issuer · Disposed 63 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $247.20 · Expires 2031-09-22 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-12 · Disposition to issuer · Disposed 121 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.00 · Expires 2032-11-16 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-12 · Disposition to issuer · Disposed 192 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction.
Sorrento Therapeutics, Inc.
Report date November 26, 2018 · Filed November 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.57 · Expires 2028-11-26 | Direct | 100,000 |
Reported balance
After 2018-11-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-26 · Grant · Acquired 100,000 · Balance 100,000 F1: 1/4th of the original number of shares subject to the option shall vest on November 26, 2019 and 1/48th of the original number of shares subject to the option shall vest following each one month period of service after November 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the original number of shares subject to the option shall vest on November 26, 2019 and 1/48th of the original number of shares subject to the option shall vest following each one month period of service after November 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Streamex Corp.
Report date July 14, 2020 · Filed July 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units ("RSUs")SEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2020-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-14 · Grant · Acquired 50,000 · Balance 50,000 F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of common stock. F2: This RSU award was granted on July 14, 2020 (the "Date of Grant"). The first 16,666 RSUs of this award shall vest and become issuable on July 14, 2021, and the remaining 33,334 RSUs shall vest in substantially equal quarterly installments and become issuable on the last day of each of the next seven calendar quarters, with the last remaining RSUs vesting and becoming issuable on the third anniversary of the Date of Grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the terms and conditions of the issuer's standard form of Restricted Stock Unit Award Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of common stock.
F2: This RSU award was granted on July 14, 2020 (the "Date of Grant"). The first 16,666 RSUs of this award shall vest and become issuable on July 14, 2021, and the remaining 33,334 RSUs shall vest in substantially equal quarterly installments and become issuable on the last day of each of the next seven calendar quarters, with the last remaining RSUs vesting and becoming issuable on the third anniversary of the Date of Grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the terms and conditions of the issuer's standard form of Restricted Stock Unit Award Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2021 Filed Feb 16, 2021 14:57 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 351,016 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010678 · doc4.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Executive VP of Research & Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,016 Underlying: Common Stock · 351,016 shares Expires 2025-02-11 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on the first anniversary of the grant date (the "Initial Vesting Date") (2/11/2021) and 1/48 of the shares subject to the option shall vest on each month anniversary of the Initial Vesting Date such that after four (4) years, all shares subject to the option shall be vested, subject to the participant's continuous service on each such vesting date. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000462 · edgar.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021 and vests over one year in twelve equal monthly installments, commencing on February 6, 2021. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000462 · edgar.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 F1 · shares: Restricted stock units ("RSUs") granted on January 6, 2021 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2021 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 6, 2022. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:36 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 15,228 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001213900-20-027375 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,228 Underlying: Common Stock · 15,228 shares Expires 2030-09-15 F1 · security: The stock option vests ratably on each of December 16, 2020, March 16, 2021, June 16, 2021 and September 16, 2021. F1 · derivative.exercise_date: The stock option vests ratably on each of December 16, 2020, March 16, 2021, June 16, 2021 and September 16, 2021. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:10 UTC | Streamex Corp. BSGM · Entity 1816 | GrantRestricted Stock Units ("RSUs") · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001185185-20-001007 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of common stock. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of common stock. F2 · derivative.exercise_date: This RSU award was granted on July 14, 2020 (the "Date of Grant"). The first 16,666 RSUs of this award shall vest and become issuable on July 14, 2021, and the remaining 33,334 RSUs shall vest in substantially equal quarterly installments and become issuable on the last day of each of the next seven calendar quarters, with the last remaining RSUs vesting and becoming issuable on the third anniversary of the Date of Grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the terms and conditions of the issuer's standard form of Restricted Stock Unit Award Agreement. F2 · derivative.expiration_date: This RSU award was granted on July 14, 2020 (the "Date of Grant"). The first 16,666 RSUs of this award shall vest and become issuable on July 14, 2021, and the remaining 33,334 RSUs shall vest in substantially equal quarterly installments and become issuable on the last day of each of the next seven calendar quarters, with the last remaining RSUs vesting and becoming issuable on the third anniversary of the Date of Grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the terms and conditions of the issuer's standard form of Restricted Stock Unit Award Agreement. Read SEC document |
| May 28, 2020 Filed May 28, 2020 10:58 UTC | Streamex Corp. BSGM · Entity 1816 | PurchaseCommon Stock | 1,000 | $10.49 | $10,488.90 |
DisclosureSEC source: 0001185185-20-000739 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,944 Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 11:50 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001185185-20-000480 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-14 F1 · derivative.exercise_date: The option vested in full on April 14, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:44 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000054 · wf-form4_158050707735698.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020 and vests over one year in twelve equal monthly installments, commencing on February 29, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:44 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000054 · wf-form4_158050707735698.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · shares: Restricted stock units ("RSUs") granted on January 29, 2020 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 10, 2020 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 29, 2021. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| November 19, 2019 Filed Nov 19, 2019 21:19 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock | 2,000 | $0.93 | $1,850.00 |
DisclosureSEC source: 0001213900-19-024072 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,917 Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 14:59 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 29,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001185185-19-001472 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2029-10-30 F1 · derivative.exercise_date: The option vested on October 30, 2019. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 20:19 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock | 4,000 | $0.94 | $3,740.00 |
DisclosureSEC source: 0001213900-19-018664 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,917 Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 22:41 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 30,928 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001213900-19-017658 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,928 Underlying: Common Stock · 30,928 shares Expires 2029-09-05 F1 · security: The stock option vests ratably on each of December 6, 2019, March 6, 2020, June 6, 2020 and September 6, 2020. F1 · derivative.exercise_date: The stock option vests ratably on each of December 6, 2019, March 6, 2020, June 6, 2020 and September 6, 2020. Read SEC document |
| May 22, 2019 Filed May 22, 2019 17:02 UTC | Streamex Corp. BSGM · Entity 1816 | Exercise / conversionWarrants to Purchase Common Stock · Derivative | 1,097 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0001185185-19-000802 · ownership.xml · derivative · entry 7 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,097 shares Expires 2021-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2019 Filed May 22, 2019 17:02 UTC | Streamex Corp. BSGM · Entity 1816 | Exercise / conversionOptions to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001185185-19-000802 · ownership.xml · derivative · entry 6 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2019 Filed May 22, 2019 17:02 UTC | Streamex Corp. BSGM · Entity 1816 | Exercise / conversionCommon Stock | 1,097 | $6.85 | $7,514.45 |
DisclosureSEC source: 0001185185-19-000802 · ownership.xml · nonDerivative · entry 4 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2019 Filed May 22, 2019 17:02 UTC | Streamex Corp. BSGM · Entity 1816 | Exercise / conversionCommon Stock | 20,000 | $3.40 | $68,000.00 |
DisclosureSEC source: 0001185185-19-000802 · ownership.xml · nonDerivative · entry 3 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2019 Filed May 22, 2019 17:02 UTC | Streamex Corp. BSGM · Entity 1816 | ConversionSeries C Preferred Stock · Derivative | 50 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001185185-19-000802 · ownership.xml · derivative · entry 5 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Series C Preferred Stock could be converted at any time at the option of the holder into shares of common stock at a conversion price of $3.75 per share. The Series C Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series C Preferred Stock could be converted at any time at the option of the holder into shares of common stock at a conversion price of $3.75 per share. The Series C Preferred Stock had no expiration date. Read SEC document |
| May 21, 2019 Filed May 22, 2019 17:02 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 3,804 | $7.44 | $28,301.76 |
DisclosureSEC source: 0001185185-19-000802 · ownership.xml · nonDerivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,847 F1 · shares: Each share of the Series C Preferred Stock is entitled to a nine percent (9%) annual dividend on the $1,000 per share stated value. The dividends accrued and became payable in cash or, at the Issuer's option and subject to the satisfaction of certain conditions, in pay-in-kind shares. Such cumulative dividends were payable quarterly, commencing on September 30, 2013, thereafter quarterly on December 31, March 31, June 30 and September 30, and on the conversion date. The reporting person's 50 shares of Series C Preferred Stock were converted on May 21, 2019, and the Issuer elected to pay the accrued dividends in pay-in-kind shares. Pursuant to the terms of the Series C Preferred Stock and using the price calculated pursuant to the terms of the Series C Preferred Stock, the reporting person received 3,804 shares of common stock as a payment-in-kind dividend upon conversion of 50 shares of Series C Preferred Stock owned by the reporting person on the conversion date. F1 · price: Each share of the Series C Preferred Stock is entitled to a nine percent (9%) annual dividend on the $1,000 per share stated value. The dividends accrued and became payable in cash or, at the Issuer's option and subject to the satisfaction of certain conditions, in pay-in-kind shares. Such cumulative dividends were payable quarterly, commencing on September 30, 2013, thereafter quarterly on December 31, March 31, June 30 and September 30, and on the conversion date. The reporting person's 50 shares of Series C Preferred Stock were converted on May 21, 2019, and the Issuer elected to pay the accrued dividends in pay-in-kind shares. Pursuant to the terms of the Series C Preferred Stock and using the price calculated pursuant to the terms of the Series C Preferred Stock, the reporting person received 3,804 shares of common stock as a payment-in-kind dividend upon conversion of 50 shares of Series C Preferred Stock owned by the reporting person on the conversion date. Read SEC document |
| May 21, 2019 Filed May 22, 2019 17:02 UTC | Streamex Corp. BSGM · Entity 1816 | ConversionCommon Stock | 13,334 | $3.75 | $50,002.50 |
DisclosureSEC source: 0001185185-19-000802 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2019 Filed Apr 22, 2019 20:41 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock | 10,000 | $0.73 | $7,274.00 |
DisclosureSEC source: 0001213900-19-006872 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,917 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.7198 to $0.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003202 · a4.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over one year in twelve equal monthly installments, commencing on February 22, 2019. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 19:49 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000850261-18-000047 · wf-form4_154336616857215.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-11-26 F1 · derivative.exercise_date: 1/4th of the original number of shares subject to the option shall vest on November 26, 2019 and 1/48th of the original number of shares subject to the option shall vest following each one month period of service after November 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 21:09 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 17,964 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001213900-18-013232 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,964 Underlying: Common Stock · 17,964 shares Expires 2028-09-26 F1 · security: The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019. F1 · derivative.exercise_date: The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 14,000 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001070081-18-000023 · wf-form4_151518696647616.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: This option was granted on January 3, 2018 and vests over one year in twelve equal monthly installments, commencing on February 3, 2018. Read SEC document |
| October 11, 2017 Filed Nov 21, 2017 19:52 UTC | MetaStat, Inc. MTST · Entity 170270 | Exercise / conversionRestricted Stock Unit · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-17-001841 · form4-11212017_041110.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock. F1 · price: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control. F2 · derivative.expiration_date: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 21:45 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-048361 · v475327_4.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-09-14 F1 · derivative.exercise_date: 1/4 of the original number of shares subject to the option shall vest on September 14, 2018 and 1/48 of the original number of shares subject to the option shall vest following each one month period of service after September 14, 2018, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 30, 2017 Filed Jul 3, 2017 13:46 UTC | Adynxx, Inc. ALQA · Entity 155807 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001144204-17-035405 · v470264_4.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2027-06-30 F1 · derivative.exercise_date: The option vests in eleven equal monthly installments with one-eleventh (1/11) vesting on the thirtieth (30th) day of each of the next eleven (11) months (or, if there is no 30th day in a month, on the last day of that month), with the first such vesting date occurring on July 30, 2017, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| June 23, 2017 Filed Jun 26, 2017 10:05 UTC | Adynxx, Inc. ALQA · Entity 155807 | OtherCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-033926 · v469565_4.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,750 F1 · kind: Pursuant to a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated February 27, 2017, with the Issuer, the Reporting Person purchased in a private placement (the "Private Placement") 400,000 shares of Common Stock at a purchase price of $0.50 per share (the "Per Share Purchase Price"). The Securities Purchase Agreement contains a "most-favored nation" provision that provides that if the Issuer, during 120 days from February 27, 2017, issues or sells any Common Stock or Common Stock equivalents reasonably believed to be more favorable in terms or conditions than the Private Placement, the Issuer must amend the terms of the Securities Purchase Agreement to give the Private Placement investors, including the Reporting Person, the benefit of such more favorable terms or conditions. F2 · kind: In accordance with this provision, effective as of April 11, 2017, following a public offering of Common Stock at a purchase price of $0.40 per share (the "Public Offering Price") on April 3, 2017, the Issuer adjusted the Per Share Purchase Price to the Public Offering Price and is required to issue additional shares of Common Stock to the Private Placement investors, including the Reporting Person, which issuance is subject to stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market and certain side letter agreement, dated March 13, 2017, between the Issuer and the Reporting Person (the "Side Letter"). F3 · kind: Pursuant to the Securities Purchase Agreement and subject to the Side Letter, on June 23, 2017, the Issuer obtained stockholder approval and issued 100,000 shares of Common Stock to the Reporting Person. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:20 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006379 · f4060817zeldis_soligenix.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| April 04, 2017 Filed Apr 6, 2017 20:00 UTC | MetaStat, Inc. MTST.OB · Entity 170270 | PurchaseCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-17-000625 · form4-04062017_080418.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Reflects the issuance of 20,000 restricted shares of fully vested common stock approved by the board of directors on April 4, 2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 06:04 UTC | Adynxx, Inc. ALQA · Entity 155807 | PurchaseCommon Stock | 400,000 | $0.50 | $200,000.00 |
DisclosureSEC source: 0001144204-17-011952 · v460790_4.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,750 Read SEC document |
| February 03, 2017 Filed Feb 3, 2017 19:43 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | PurchaseCommon Stock | 10,000 | $5.15 | $51,500.00 |
DisclosureSEC source: 0000899243-17-002778 · doc4.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 12,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001070081-17-000041 · wf-form4_148366230507066.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-01-02 F1 · derivative.exercise_date: This option was granted on January 3, 2017 and vests over one year in twelve equal monthly installments, commencing on February 3, 2017. Read SEC document |
| December 22, 2016 Filed Feb 9, 2017 17:03 UTC | Streamex Corp. BSGM · Entity 1816 | GrantOptions to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001185185-17-000247 · form4-zeldis020917.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-22 Read SEC document |
| August 12, 2016 Filed Nov 15, 2016 19:22 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0000899243-16-033607 · doc4.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2026-08-12 F1 · derivative.exercise_date: 1/4 of the original number of shares subject to the option shall vest on August 12, 2017 and 1/48 of the original number of shares subject to the option shall vest following each one month period of service after August 12, 2017, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.